Clinical Trials
2 trialsNCT03679624 2023-10-23
Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03187262 2022-11-23
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed